NCT05363293View on ClinicalTrials.gov

Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 4, 2022

Primary Completion Date

April 14, 2023

Study Completion Date

May 15, 2023

Conditions
Alzheimer's DiseaseHealthy Non-elderly and Elderly Adults
Interventions
DRUG

AL001

a crystal engineered lithium-salicylate-proline lithium delivery product

OTHER

Placebo

matching placebo formulation

Trial Locations (2)

30030

CenExel iResearch, LLC, Decatur

H3P 3P1

Altasciences, Mount Royal

Sponsors
All Listed Sponsors
lead

Alzamend Neuro, Inc.

INDUSTRY